Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation

NCT03879174 is registered in ClinicalTrials.gov with Mediclinic Middle East as lead sponsor.

NCT NCT03879174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03879174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation
Lead sponsor
Mediclinic Middle East
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2019
Completion date
August 1, 2022
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female